.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,655,636

« Back to Dashboard

Claims for Patent: 7,655,636

Title:Use of A2A adenosine receptor agonists
Abstract:The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, -- an adenosine A.sub.2A receptor agonist -- to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.
Inventor(s): Gordi; Toufigh (Sunnyvale, CA), Olmsted; Ann Walls (Palo Alto, CA), Lieu; Hsiao Dee (Burlingam, CA), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Palo Alto, Inc. (Foster City, CA)
Application Number:11/253,322
Patent Claims: 1. A method of producing coronary vasodilation with little peripheral vasodilation comprising administering to a human a single intravenous (iv) bolus dose of a pharmaceutical composition comprising regadenoson, a compound named (l-{9-[(4S, 2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}p- yrazol-4-yl)-N-methylcarboxamide, which has the formula: ##STR00002## and at least one pharmaceutical excipient in an amount that is sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.

2. The method of claim 1 wherein said single dose of a pharmaceutical composition is administered in about 10 to about 20 seconds.

3. The method of claim 1 wherein the amount of the single dose of a pharmaceutical composition administered is sufficient to raise the average coronary peak flow velocity by an amount ranging from about 16.5 to about 77.0 cm/sec.

4. The method of claim 1 wherein the single dose of pharmaceutical composition includes from about 10 to about 500 micrograms of regadenoson.

5. The method of claim 1 wherein the single dose of pharmaceutical composition includes an amount of regadenoson ranging from about 0.05 to about 60 .mu.g/kg.

6. The method of claim 1 wherein myocardial perfusion imaging of a human is performed following administration of the single dose of the pharmaceutical composition to the human.

7. The method of claim 6 further comprising administering at least one radionuclide to the human at a time selected from the group consisting of before the human receives the dose of pharmaceutical composition, simultaneously with the administration of the dose of pharmaceutical composition or after administering the dose of pharmaceutical composition to the human.

8. The method of claim 6 wherein the radionuclide and the single dose of the pharmaceutical composition are administered separately to the human.

9. The method of claim 6 wherein the radionuclide and the single dose of the pharmaceutical composition are administered simultaneously to the human.

10. The method of claim 6 wherein the myocardium examination begins no sooner than about 1 minute from the time the single dose of the pharmaceutical composition is administered to the human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc